Katya Ascher focuses her practice on patent law issues in litigation and transactional matters across technology sectors. She regularly negotiates every type of agreement associated with technology transfer, research and development, manufacturing and distribution. She has over a decade of experience counseling clients in the United States, France, and the United Kingdom. Her clients include mid-sized companies and start-ups, operating in the biotechnology, pharmaceutical, medical device, and engineering fields.
Katya Ascher spent the first five years of her career as an associate in one of the top New York intellectual property boutiques where she litigated cases in district court and the International Trade Commission and advised clients on patent validity and infringement. She subsequently worked as the intellectual property counsel in a French research foundation and as a solicitor in London. Before studying law, Katya gained technical experience as an intern in a genomic research laboratory of a major biotechnology company.
Advised Corlieve Therapeutics on its sale to uniQure, with its lead program, a gene therapy approach to treat Temporal Lobe Epilepsy
Advised Pierre Fabre on its license to ValenzaBio on an anti-IGF-1R antibody for the development of a novel treatment in Thyroid Eye Disease
Advised Ardian Growth and BNP Paribas Development on their investment into Proteor, a manufacturer and distributor of prosthetics and orthotics
University of Paris II Panthéon-Assas, Master 2 Industrial Property, 2012
University of North Carolina School of Law, JD, with honors, 2005
University of North Carolina at Chapel Hill, BA, Biology, with distinction, 2002
Do not send any information or documents that you want to have treated as secret or confidential. Providing information to McDermott via email links on this website or other introductory email communications will not create an attorney-client relationship; will not preclude McDermott from representing any other person or firm in any matter; and will not obligate McDermott to keep confidential the information you provide. McDermott cannot enter into an attorney-client relationship with you until McDermott has determined that doing so will not create a conflict of interest and until you and McDermott have entered into a written agreement or engagement letter that sets forth the terms of our relationship.